Intron A (interferon-alpha-2b recombinant) for injection/Schering-Plough Corporation.
Intron A (Interferon-alpha-2b Recombinant) for injection, a product by Schering-Plough Corporation, is a recombinant DNA, genetically engineered copy of a naturally occurring protein which acts as an antiviral agent. This product is now approved in the United States for the treatment of chronic non-A, non-B hepatitis, also known as hepatitis C. Intron A represents an important advance in the treatment of chronic hepatitis non-A, non-B/C because until now, although many other drugs have been tried, there has been no effective treatment.
Swartz
M L
ML
D002986:Clinical Trials as Topic; D000075202:Contraindications; D006526:Hepatitis C / Q000451:nursing / Q000628:therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D011994:Recombinant Proteins
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins